Cargando…
843. Targeted HIV Testing for Patients Hospitalized for COVID-19
BACKGROUND: SARS-CoV-2 causes a severe respiratory illness known as COVID-19. Treatment options in the early portion of the COVID-19 pandemic included the use of antiretroviral agents i.e. protease inhibitors (PIs) such as lopinavir (LPV) that had been shown to have activity against the main proteas...
Autores principales: | Virata, Michael D, Villanueva, Merceditas, Miceli, Janet |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643876/ http://dx.doi.org/10.1093/ofid/ofab466.1038 |
Ejemplares similares
-
543. SARS-CoV-2 Viral Dynamics For Symptomatic People Living with HIV Requiring Hospitalization For COVID-19
por: Virata, Michael D, et al.
Publicado: (2020) -
111. Outcomes Related to COVID-19 Among People Living with HIV: Cohort from a Large Academic Center
por: Virata, Michael D, et al.
Publicado: (2020) -
843. Increased Carbapenemase Testing Following Implementation of VA Guidelines for Carbapenem-Resistant Enterobacteriaceae (CRE)
por: Fitzpatrick, Margaret A, et al.
Publicado: (2020) -
1311. Ryan White HIV Care Continuum Model Doubled the Rate of Community HIV Viral Suppression for Newly Diagnosed Patients: A 10-Year Review
por: Rizk, Christina, et al.
Publicado: (2019) -
2234. Implementing a Co-located HCV Clinic Within an HIV Clinic: Four Year Experience
por: Villanueva, Merceditas, et al.
Publicado: (2018)